INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Grant or awardVerified data

Rieger Jayson reported VRCA

Director, CEO and President · Verrica Pharmaceuticals Inc. · Verrica Pharmaceuticals Inc. — Employee Stock Option (right to buy)

Side
A
Value
—
Shares
512.3K
Price
—
Executed
Jun 5, 2026
Disclosed
Jun 9, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jun 5 executedJun 9, 2026 disclosed

VRCA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
5/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    2 prior trades recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · VRCA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    30
    RJ
    Rieger JaysonDirector, CEO and President
    VRCAVerrica Pharmaceuticals Inc.
    Open-market purchase
    		BUY$25K
    5,000 sh
    		Aug 17, 2026Aug 18, 2026
    traded Aug 17, 2026
    		+1dSEC FORM 4

    Evidence

    37
    RJ
    Rieger JaysonDirector, CEO and President
    VRCAVerrica Pharmaceuticals Inc.
    Open-market purchase
    		BUY$101K
    20.0K sh
    		Aug 14, 2026Aug 18, 2026
    traded Aug 14, 2026
    		+4dSEC FORM 4

    Evidence

    38
    ZD
    Zawitz DavidChief Operating Officer
    VRCAVerrica Pharmaceuticals Inc.
    Open-market purchase
    		BUY$30K
    6,000 sh
    		Aug 17, 2026Aug 18, 2026
    traded Aug 17, 2026
    		+1dSEC FORM 4

    Evidence

    5
    ZD
    Zawitz DavidChief Operating Officer
    VRCAVerrica Pharmaceuticals Inc.
    Grant or award
    		A—
    171.3K sh
    		Jun 5, 2026Jun 9, 2026
    traded Jun 5, 2026
    		+4dSEC FORM 4

    Evidence

    9
    EL
    Eichenfield LawrenceDirector
    VRCAVerrica Pharmaceuticals Inc.
    Grant or award
    		A—
    16.0K sh
    		Jun 5, 2026Jun 9, 2026
    traded Jun 5, 2026
    		+4dSEC FORM 4

    Evidence

    9
    ND
    Nguyen DiemDirector
    VRCAVerrica Pharmaceuticals Inc.
    Grant or award
    		A—
    16.0K sh
    		Jun 5, 2026Jun 9, 2026
    traded Jun 5, 2026
    		+4dSEC FORM 4

    Evidence

    46
    RJ
    Rieger JaysonDirector, CEO and President
    VRCAVerrica Pharmaceuticals Inc.
    Open-market purchase
    		BUY—
    23.6K sh
    		Nov 25, 2025Nov 25, 2025
    traded Nov 25, 2025
    		+0dSEC FORM 4

    Evidence

    52
    RJ
    Rieger JaysonDirector, CEO and President
    VRCAVerrica Pharmaceuticals Inc.
    Open-market purchase
    		BUY$400K
    94.3K sh
    		Nov 25, 2025Nov 25, 2025
    traded Nov 25, 2025
    		+0dSEC FORM 4

    Evidence

    46
    ZD
    Zawitz DavidChief Operating Officer
    VRCAVerrica Pharmaceuticals Inc.
    Open-market purchase
    		BUY—
    2,500 sh
    		Nov 25, 2025Nov 25, 2025
    traded Nov 25, 2025
    		+0dSEC FORM 4

    Evidence

    46
    ZD
    Zawitz DavidChief Operating Officer
    VRCAVerrica Pharmaceuticals Inc.
    Open-market purchase
    		BUY$42K
    10.0K sh
    		Nov 25, 2025Nov 25, 2025
    traded Nov 25, 2025
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002043558-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 5, 2026
    Published
    Jun 9, 2026
    Ingested by INSIDER
    Nov 5, 03:54 UTC
    Last re-read
    Nov 5, 03:54 UTC

    Extracted facts

    Filer
    Rieger Jayson
    Role
    Director, CEO and President
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Verrica Pharmaceuticals Inc. — Employee Stock Option (right to buy)
    Ticker
    VRCA
    Shares
    512.3K
    Price per share
    $0
    Execution date (reported)
    Jun 5, 2026
    Owned after transaction
    512.3K shares
    Days from execution to publication
    4

    What this establishes

    Rieger Jayson filed this Form 4 reporting a grant or award of VRCA on Jun 5, 2026. It became public on Jun 9, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, CEO and President
    Rieger Jaysoncik:0002043558
    Issuer
    Verrica Pharmaceuticals Inc.cik:0001660334

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.